Bristol-Myers Squibb stock trades lower with weekly decline intensifying amid bearish momentum

Traders Union
All News
Companies
Bristol-Myers Squibb down 1.11% today

Highlights

BMY trades below short- and medium-term moving averages, reflecting persistent selling pressure and a dominant bearish trend.
Bearish momentum is confirmed by oversold technical indicators and the stock closing 1.11% lower, at the bottom of its weekly range.
Despite ongoing weakness, strong weekly signals suggest a greater than 80% chance of a short-term bounce, with an expected price range of $54.20 to $56.80.

Seller pressure persists as price holds above long-term support

BMY is currently trading at $55.30, which places it below the MA-20 ($56.87) and MA-50 ($57.52), indicating short- and medium-term pressure from sellers, but above the MA-200 ($53.51), which points to ongoing long-term support. The Ichimoku Kijun on D1 sits at $57.19, marking immediate resistance just above the current price; near-term support is identified at the MA-200 ($53.51) with key support at MA-100 ($58.39), while near-term resistance is the MA-20 ($56.87) and key resistance aligns with both the MA-50 ($57.52) and the Ichimoku Kijun ($57.19) cluster.

Negative momentum confirmed as oversold readings deepen weekly downside

Bearish momentum is confirmed by a strong sell signal from the MACD and a weak, neutral trend as indicated by ADX on D1. Multiple oscillators, including RSI (45.70), Stoch RSI (Sell), and CCI (-63.60), signal ongoing selling pressure and an oversold condition, while BBP highlights seller dominance with an "oversold" reading. The Awesome Oscillator aligns with the prevailing downward bias. In today's session, BMY is down 1.11% from the previous close, reflecting notable downward momentum. Over the past week, BMY has fallen $1.83, or 3.20%, from a prev_week_close of $57.13. The current price sits at the very bottom of the weekly range, with weekly volatility standing at 3.82%. The week’s tone is marked by steady decline from the highs, reinforcing negative momentum.

Bullish reversal favored as scenario analysis weighs support resilience

Looking ahead, the expected price range for the coming week is $54.20 to $56.80, which sits well above the 52-week low of $42.52 and remains short of the 52-week high of $62.89. Based on W1 signals—one strong buy from MACD, one buy from ADX, and two buy signals from MA-50 (SMA and EMA)—the probability of a price increase is very high (more than 80%), making a decline less likely in the next five to seven days. The baseline scenario sees BMY fluctuating sideways just above the long-term MA-200 support. In a bullish scenario, price action above $56.87 could trigger a move toward $57.50–$58.00. In a bearish scenario, a drop below $54.20 risks retesting the long-term MA-200 and moving closer to the lower boundary for the week.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Bristol-Myers Squibb was experiencing continued downside pressure with limited short-term upside potential. This article expands on that outlook by examining recent market action and highlights that the prevailing scenario remains one of caution, with investors advised to closely monitor for any shift in momentum or a notable move above current resistance levels.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.